Neurogene Common Stock share price logo

Neurogene Common Stock

NASDAQ: NGNE

Small Cap

$30.86

-1.39

(-4.31%)

as on

Neurogene Common Stock Stock Performance

as on June 24, 2026 at 2:15 pm IST

  • Day's High

    $30.86
    $32.61

    5.67%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $14.65
    $37.27
    downward going graph

    52.53%

    Downside

    20.76%

    Upside

    downward going graph

Neurogene Common Stock share price movements today

Previous Close
$32.25
Open
$31.84
Volume
412.1K
Day's Low - High
$30.86 - $32.61
52 Week Low - High
$14.65 - $37.27

Neurogene Common Stock Historical Returns

1 Month Return
+ 11.37 %
3 Month Return
+ 47.66 %
1 Year Return
+ 79.42 %
3 Year Return
0 %
5 Year Return
0 %

Neurogene Common Stock Stock Fundamentals & Key Indicators

Check Neurogene Common Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$509.6M

EPS (TTM)

-5.4067

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-107.5M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-37.25%

Neurogene Common Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Neurogene Common Stock with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$509.6MNANA0.00%NA
BUY$38.2B65.93%71.9612.55%NA
BUY$118.5B144.05%27.735.51%NA
BUY$64.2B13.51%14.9529.65%0.59%

Stock Returns calculator for Neurogene Common Stock Stock including INR - Dollar returns

The Neurogene Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Neurogene Common Stock investment value today

Current value as on today

₹1,96,318

Returns

₹96,318

(+96.32%)

Returns from Neurogene Common Stock Stock

₹79,419 (+79.42%)

Dollar Impact

₹16,900 (+16.9%)

Analyst Recommendation on Neurogene Common Stock Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Neurogene Common Stock. Average target price of $80

Neurogene Common Stock Share Price Target

Get share price movements and forecasts by analysts on Neurogene Common Stock.

What analysts predicted

61.43%UPSIDE

Target Price

$80

Current Price

$30.86

Analyzed by

11 Analysts

Target

$80.00

Neurogene Common Stock target price $80, a slight upside of 61.43% compared to current price of $30.86. According to 11 analysts rating.

Indian Investors' Interest in Neurogene Common Stock Stock

Search interest for Neurogene Common Stock Stock has decreased by -10% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-10% versus previous 30 day period

Neurogene Common Stock Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
-
-
0
-
0
-
-
-
-
-
Gross Profit
-12
0
0
0
-15
-17
-19
-17
0
0
Operating Income
-14
-18
-20
-22
-21
-25
-26
-23
-27
-33
EBITDA
3
-16
-17
-19
-18
-21
-21
-20
-23
-30
Interest Expense
0
0
0
0
0
0
0
0
0
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
2
-16
-18
-20
-19
-22
-22
-20
-24
-30
Income Tax Expense
1
0
0
-
-
-
-
-
-
-
Net Income
2
-16
-18
-20
-19
-22
-22
-20
-24
-30
Net Profit Margin
0.00%
0.00%
-1999.14%
0.00%
2109.62%
0.00%
0.00%
0.00%
0.00%
0.00%

Neurogene Common Stock Annual Profit & Loss

All numbers in Millions USD

Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
0
-
Gross Profit
-42
-
-3
-
-3
-2
-3
Operating Income
-50
-
-56
-
-55
-82
-103
EBITDA
-49
-
-51
-
-33
-71
-87
Interest Expense
-
-
0
-
0
0
0
Depreciation
0
-
3
-
3
3
3
Income Before Tax
-50
-
-55
-
-36
-75
-90
Income Tax Expense
0
-
0
-
0
-
-
Net Income
-50
-50
-55
-55
-36
-75
-90
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
-8123.68%
0.00%

Neurogene Common Stock Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-16
-18
-20
-19
-22
-22
-20
-24
-30
Operating Cash Flow
-21
-15
-15
-17
-20
-19
-19
-16
-26
Investing Cash Flow
29
-23
-28
-102
-45
7
22
29
46
Financing Cash Flow
-6
0
0
190
0
0
9
20
0
Change in Cash
1
-39
-44
69
-65
-11
12
32
20

Neurogene Common Stock Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-50
-31
-8
-33
-50
-55
-36
-75
-90
Operating Cash Flow
-44
-31
-15
-24
-46
-52
-51
-70
-77
Investing Cash Flow
64
55
0
-2
-18
-2
25
-125
14
Financing Cash Flow
0
0
82
77
51
66
92
184
30
Change in Cash
19
24
66
49
-13
11
66
-11
-32

Global Institutional Holdings in Neurogene Common Stock

Funds
Holdings
State Street Corp
1.98%
Casdin Capital, LLC
8.99%
Millennium Management LLC
1.31%
EcoR1 Capital, LLC
8.05%
BlackRock Inc
6.36%

Insights on Neurogene Common Stock

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, NGNE has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, NGNE stock has moved up by 47.7%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, NGNE has outperformed top 5 stocks with highest market-cap in its industry

About Neurogene Common Stock

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
OrganisationNeurogene Common Stock
Headquarters535 W 24th Street, New York, NY, United States, 10011
IndustryBiotechnology
CEODr. Rachel L. McMinn Ph.D.
E-voting on sharesClick here to vote

Key Management of Neurogene Common Stock

Name

Title

Dr. Julie Jordan M.D.

Chief Medical Officer

Dr. Stuart Cobb Ph.D.

Chief Scientific Officer

Ms. Donna M. Cochener-Metcalfe J.D., L.L.M.

Senior VP, General Counsel & Corporate Secretary

Mr. Ricardo Jimenez

Senior Vice President of Technical Operations

Mr. Arvind Sreedharan

Senior Vice President of Business Operations

Ms. Christine Mikail Cvijic J.D.

President, CFO & Director

Dr. Andrew E. Mulberg CPI, FAAP, M.D.

Senior VP of Regulatory Affairs, Quality Assurance & Quality Control

Ms. Christina Shafer

Chief Commercial Officer

Dr. Rachel L. McMinn Ph.D.

Founder, Executive Chair & CEO

FAQs

What is Neurogene Common Stock share price today?

Neurogene Common Stock share price today is $30.86 as on at the close of the market. Neurogene Common Stock share today touched a day high of $32.61 and a low of $30.86.

What is the 52 week high and 52 week low for Neurogene Common Stock share?

Neurogene Common Stock share touched a 52 week high of $37.27 on and a 52 week low of $14.65 on . Neurogene Common Stock stock price today i.e. is closed at $30.86,which is 17.19% down from its 52 week high and 110.65% up from its 52 week low.

What is Neurogene Common Stock's market capitalisation today?

Neurogene Common Stock market capitalisation is $0.00T as on .

How to invest in Neurogene Common Stock Stock (NGNE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Neurogene Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Neurogene Common Stock Shares that will get you 0.0486 shares as per Neurogene Common Stock share price of $30.86 per share as on June 24, 2026 at 8:45 am IST.

What is the minimum amount required to buy Neurogene Common Stock Stock (NGNE) from India?

Indian investors can start investing in Neurogene Common Stock (NGNE) shares with as little as ₹94.735 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹947.35 in Neurogene Common Stock stock (as per the Rupee-Dollar exchange rate as on ). Based on Neurogene Common Stock share’s latest price of $30.86 as on June 24, 2026 at 8:45 am IST, you will get 0.3240 shares of Neurogene Common Stock. Learn more about fractional shares .